moneyheap
JNJ · Analysis updated Nov 10, 2026, 6:00 PM ET
Why is Johnson & Johnson (JNJ) stock moving?
JNJ closed at 280.78 on Nov 10, up about 4.9% from 267.61 on Oct 22 and holding near the top of its 30-day range (259.04 to 283.25). News flow over the past two weeks is mostly positive: an FDA accelerated approval for RYBREVANT FASPRO in head and neck cancer (Nov 6), positive Phase 3 data for ICOTYDE in psoriatic arthritis (Nov 8), and a second positive Phase 3 CAPLYTA study in bipolar mania (Nov 10), plus supporting Phase 1 and ACR data. The main negative is a $34.21M talc-asbestos jury verdict (Nov 10), which is small against the company's scale and did not stop the stock from being roughly flat that day (-0.5% after a 282.11 close on Nov 9). Volume was elevated on Oct 22 (10.2M), Oct 30 (9.0M) and Nov 4 to 5 (about 9.7M), with the Nov 9 to 10 sessions trading 7.0M to 7.4M, suggesting the rally is steady rather than frenzied. Talc litigation remains an open risk, and the pipeline readouts mostly lie in the future, so the outlook is moderately positive without being decisive.
On the moneyheap blog
- Can Time Series Foundation Models Predict Stock Prices?Can AI predict stock prices? We ran Google's TimesFM 3.0, Amazon's Chronos-2 and Datadog's Toto 2.0 on 24 stocks for two years. Here's what they got right.
News behind the analysis
- California Jury Awards $34.21 Million in Talc-Asbestos Mesothelioma CaseA Northern California jury found Johnson & Johnson liable for failing to warn consumers about asbestos contamination in its talcum powder products.
- Johnson & Johnson Announces Positive Results from Second Phase 3 Study of CAPLYTA for Bipolar ManiaThe second pivotal Phase 3 study of CAPLYTA (lumateperone) met its primary and key secondary endpoints in adults with bipolar I disorder.
- Johnson & Johnson's Phase 3 Study Evaluating CAPLYTA Met Its Primary And Key Secondary EndpointsBenzinga reported that the second Phase 3 CAPLYTA study hit its primary and key secondary endpoints in bipolar mania.
- Johnson & Johnson Reports Positive Phase 3 Results for ICOTYDE in Psoriatic ArthritisICOTYDE (icotrokinra) showed significant improvement in disease activity in biologic-naive adults with active psoriatic arthritis in a Phase 3 study.
- Johnson & Johnson Reports Positive Phase 3 Results for ICOTYDE in Psoriatic ArthritisICOTYDE (icotrokinra) showed significant improvement in disease activity in biologic-naive adults with active psoriatic arthritis in a Phase 3 study.
- FDA Grants Accelerated Approval for RYBREVANT FASPRO in Head and Neck Squamous Cell CarcinomaThe FDA granted accelerated approval for RYBREVANT FASPRO as a single agent for adults with recurrent or metastatic head and neck squamous cell carcinoma.
- First Therapy for Advanced Head & Neck Cancer in 10 Years: Johnson & Johnson Secures Accelerated FDA NodBenzinga reported the FDA accelerated approval of RYBREVANT FASPRO for recurrent or metastatic head and neck cancer, based on the OrigAMI-4 Phase 1b/2 trial showing a 42% overall response rate.
- Johnson & Johnson Reports Phase 1 Results for Investigational Prostate Cancer CombinationPositive Phase 1 results were announced for a pasritamig and JNJ-9401 combination in advanced prostate cancer, with 73% PSA response reported.
- Johnson & Johnson's JJDC Participates in $100M Financing for Delix TherapeuticsJ&J's venture arm JJDC took part in a $100 million financing round for Delix Therapeutics, which develops psychedelic-inspired treatments.
About Johnson & Johnson
Johnson & Johnson is a large US healthcare company based in New Brunswick, New Jersey, with two businesses: prescription drugs (Innovative Medicine) and medical devices (MedTech). Its consumer health arm was spun off as Kenvue, so J&J now focuses only on medicines and devices, and it expects 2026 sales of about $101 billion, the first time it will top $100 billion.
How it makes money
Most of its revenue, roughly two-thirds, comes from selling prescription drugs. Key products include Darzalex for blood cancer (about $4.2B in Q3 2026), Tremfya for psoriasis and Crohn's disease (about $2.4B in Q3 2026 and growing fast) and Stelara, an older immune drug whose sales are falling quickly now that cheaper copies (biosimilars) are on the market. The other roughly one-third comes from MedTech: surgical tools and robots, heart devices such as electrophysiology systems, orthopedics (which J&J plans to spin off) and vision products. About 59% of sales come from the US.
What usually moves JNJ
- New drug approvals and late-stage trial results
- Biosimilar competition eroding Stelara sales
- Talc lawsuits and settlement costs
- MedTech growth and orthopedics spinoff
- US drug pricing policy and tariffs